Can a single drug make stem cell recovery less miserable for older patients?
NCT ID NCT03315026
First seen Nov 04, 2025 · Last updated Apr 28, 2026 · Updated 30 times
Summary
This study looks at whether giving siltuximab before and after an autologous stem cell transplant can reduce common side effects like fatigue, pain, and nausea in patients aged 60-75 with multiple myeloma or AL amyloidosis. The drug blocks a protein called IL-6 that is linked to inflammation and worse symptoms after transplant. The goal is to help patients feel better and recover faster, potentially shortening hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.